Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Erythropoietin in Acute Renal Failure
NCT03102021Phase 2Completed
- Sponsor
- VA North Texas Health Care System
- Start
- Mar 2006
- Primary completion
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney injury (AKI) comparing Erythropoietin with Placebo (2 arms). Primary endpoint: Days of Acute Renal Failure at 28 days. Started Mar 2006; status: completed.
02
Drugs
erythropoietin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03102021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102021.